98%
921
2 minutes
20
Purpose: The purpose of the present study was to compare different software algorithms for processing DSC perfusion images of cerebral tumors with respect to i) the relative CBV (rCBV) calculated, ii) the cutoff value for discriminating low- and high-grade gliomas, and iii) the diagnostic performance for differentiating these tumors.
Methods: Following approval of institutional review board, informed consent was obtained from all patients. Thirty-five patients with primary glioma (grade II, 9; grade III, 8; and grade IV, 18 patients) were included. DSC perfusion imaging was performed with 3-Tesla MRI scanner. CBV maps were generated by using 11 different algorithms of four commercially available software and one academic program. rCBV of each tumor compared to normal white matter was calculated by ROI measurements. Differences in rCBV value were compared between algorithms for each tumor grade. Receiver operator characteristics analysis was conducted for the evaluation of diagnostic performance of different algorithms for differentiating between different grades.
Results: Several algorithms showed significant differences in rCBV, especially for grade IV tumors. When differentiating between low- (II) and high-grade (III/IV) tumors, the area under the ROC curve (Az) was similar (range 0.85-0.87), and there were no significant differences in Az between any pair of algorithms. In contrast, the optimal cutoff values varied between algorithms (range 4.18-6.53).
Conclusions: rCBV values of tumor and cutoff values for discriminating low- and high-grade gliomas differed between software packages, suggesting that optimal software-specific cutoff values should be used for diagnosis of high-grade gliomas.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600072 | PMC |
http://dx.doi.org/10.2463/mrms.mp.2016-0036 | DOI Listing |
J Pathol Inform
November 2025
Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA.
Evaluation of tumor infiltrating lymphocytes as recommended by current guidelines is largely based on stromal regions within the tumor. In the context of epithelial malignancies, the epithelial region and the epithelial-stromal interface are not assessed, because of technical difficulties in manually discerning lymphocytes when admixed with epithelial tumor cells. The inability to quantify immune cells in epithelial-associated areas may negatively impact evaluation of patient response to immune checkpoint therapies.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
September 2025
Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Purpose: Amino acid PET with [F]-fluoroethylthyrosine ([F]FET-PET) is frequently utilized in gliomas. Most studies on prognostication based on amino acid PET comprise mixed cohorts of brain tumors with low- and high-grade features. The objective of this study was to assess the potential prognostic value of [F]FET-PET-based markers in the group of grade 2 adult-type diffuse gliomas, as defined by the WHO CNS 2021 classification.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.
Introduction: The optimal surveillance for mucinous appendix cancer (MAC) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) remains unclear. We identified postoperative periods reflecting significant changes in recurrence probability.
Methods: A prospective database (1998-2024) of patients with stage IV MAC with low-grade (LGMCP), high-grade (HGMCP), and signet-ring cell (SRC) histology treated with initial complete (CC-0/1) CRS/HIPEC was analyzed.
Dis Colon Rectum
September 2025
Department of Surgery, Oregon Health & Science University, Portland, Oregon.
Background: Anal squamous cell cancer incidence has risen 2.2% each year over the past decade. Current screening includes anal cytology and high-resolution anoscopy but is burdened with sampling error and patient discomfort.
View Article and Find Full Text PDFCrit Rev Oncol Hematol
September 2025
Division of Thoracic Oncology, European Institute of Oncology, IEO, IRCCS, 20141, Milan, Italy.
Amivantamab, a bispecific EGFR-MET antibody, has demonstrated efficacy in EGFR-mutant non-small cell lung cancer (NSCLC) across multiple trials and is poised to enter first-line therapy. However, as with EGFR-targeted therapies, amivantamab is associated with distinctive cutaneous toxicities. This perspective summarizes clinical evidence on the frequency, nature, and severity of skin-related adverse events from key studies, outlining how, despite concerns initially raised among clinicians about its tolerability in routine practice, clinical experience indicates that amivantamab's cutaneous toxicities are manageable with proactive strategies and education.
View Article and Find Full Text PDF